Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2016; 22(28): 6424-6433
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6424
Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas
Daniel Åkerberg, Daniel Ansari, Roland Andersson
Daniel Åkerberg, Daniel Ansari, Roland Andersson, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden
Author contributions: Åkerberg D and Ansari D conducted the literature search and drafted the manuscript; Andersson R conceived the study; all authors were involved in manuscript writing and read and approved the final manuscript.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Roland Andersson, MD, PhD, Department of Surgery, Clinical Sciences Lund, Lund University, and Skåne University Hospital, SE-221 85 Lund, Sweden. roland.andersson@med.lu.se
Telephone: +46-46-172359
Received: March 24, 2016
Peer-review started: March 25, 2016
First decision: May 12, 2016
Revised: May 24, 2016
Accepted: June 15, 2016
Article in press: June 15, 2016
Published online: July 28, 2016
Core Tip

Core tip: Many studies have investigated morphological indicators of survival in patients with resectable pancreatic cancer. This article scrutinizes the recent literature related to these classical prognostic factors and examines whether these factors still are able to influence patients’ outcomes in the era of multimodal treatment.